MRNA241004C73000
- 0.09
- -0.15-62.50%
Moderna Newsroom
Deutsche Bank Cuts Moderna Price Target to $75 From $80
Moderna Analyst Ratings
RBC Capital Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $75
Goldman Sachs Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $139
Morgan Stanley Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $70
Barclays Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $125
Morgan Stanley Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $70
Brookline Capital Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $238
Moderna Continues to Decline as Oppenheimer Latest to Downgrade
Moderna Is Maintained at Hold by TD Cowen
BofA Securities Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $110
Moderna Cut to Underweight From Neutral by JP Morgan
Jefferies Downgrades Moderna to Hold, Lowers Price Target to $65
A Quick Look at Today's Ratings for Moderna(MRNA.US), With a Forecast Between $94 to $125
Moderna Analyst Ratings
Brookline Capital Cuts Price Target on Moderna to $238 From $310
RBC Cuts Price Target on Moderna to $75 From $90, Keeps Sector Perform Rating
Moderna's Strong Q3 Performance and Promising Pipeline Secure Buy Rating
Brookline Capital Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $310
Moderna Price Target Announced at $82.00/Share by HSBC